ATE346610T1 - Zusammensetzung enthaltend, ein antigen, ein th-1 induzierendes adjuvans und eine im wasser schwer lösliche aminosäure, zur verwendung in der immunisierung - Google Patents

Zusammensetzung enthaltend, ein antigen, ein th-1 induzierendes adjuvans und eine im wasser schwer lösliche aminosäure, zur verwendung in der immunisierung

Info

Publication number
ATE346610T1
ATE346610T1 AT99307406T AT99307406T ATE346610T1 AT E346610 T1 ATE346610 T1 AT E346610T1 AT 99307406 T AT99307406 T AT 99307406T AT 99307406 T AT99307406 T AT 99307406T AT E346610 T1 ATE346610 T1 AT E346610T1
Authority
AT
Austria
Prior art keywords
antigen
amino acid
immunization
composition containing
water soluble
Prior art date
Application number
AT99307406T
Other languages
English (en)
Inventor
Alan Wheeler
Anthony Berry
Original Assignee
Allergy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergy Therapeutics Ltd filed Critical Allergy Therapeutics Ltd
Application granted granted Critical
Publication of ATE346610T1 publication Critical patent/ATE346610T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT99307406T 1998-09-21 1999-09-17 Zusammensetzung enthaltend, ein antigen, ein th-1 induzierendes adjuvans und eine im wasser schwer lösliche aminosäure, zur verwendung in der immunisierung ATE346610T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9820525.5A GB9820525D0 (en) 1998-09-21 1998-09-21 Formulation

Publications (1)

Publication Number Publication Date
ATE346610T1 true ATE346610T1 (de) 2006-12-15

Family

ID=10839197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99307406T ATE346610T1 (de) 1998-09-21 1999-09-17 Zusammensetzung enthaltend, ein antigen, ein th-1 induzierendes adjuvans und eine im wasser schwer lösliche aminosäure, zur verwendung in der immunisierung

Country Status (13)

Country Link
US (2) US6440426B1 (de)
EP (1) EP0988862B1 (de)
JP (2) JP4743928B2 (de)
KR (1) KR100642877B1 (de)
AT (1) ATE346610T1 (de)
AU (1) AU766251B2 (de)
CA (1) CA2282779C (de)
DE (1) DE69934179T2 (de)
DK (1) DK0988862T3 (de)
ES (1) ES2277413T3 (de)
GB (2) GB9820525D0 (de)
NZ (1) NZ337885A (de)
PT (1) PT988862E (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380376B1 (en) * 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1366126B1 (de) * 2001-01-30 2007-05-30 Schwan-STABILO Schwanhäusser GmbH & Co. KG Markierungsflüssigkeit
DE10125731A1 (de) * 2001-05-17 2003-03-06 A I D Autoimmun Diagnostika Gm Darreichungsform von immunologischen Wirkstoffen
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US8333976B2 (en) * 2003-08-28 2012-12-18 Sandor Sipka Processes for inhibiting development of allergic disease
CA2596920C (en) * 2005-01-28 2015-05-05 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2015050181A1 (ja) * 2013-10-03 2015-04-09 日東電工株式会社 注射ワクチン組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128637A (en) 1966-09-13 1968-09-25 Beecham Group Ltd Influenza vaccine
US3541201A (en) * 1968-12-18 1970-11-17 Ethan Alan Brown Novel sodium chloride encapsulated injectionable substances
GB1377074A (en) 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
GB1492973A (en) 1974-02-16 1977-11-23 Beecham Group Ltd Process for preparing injectable compositions
US4070455A (en) 1974-02-16 1978-01-24 Beecham Group Limited Process for preparing injectable desensitizing compositions and products thereof in microparticle form
EP0182442B2 (de) 1978-12-22 1996-04-03 Biogen, Inc. Rekombinante DNS-Moleküle und Verfahren zur Herstellung derselben
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5244663A (en) 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
FR2621916B1 (fr) * 1987-10-19 1990-03-09 Bioeurope Derives de la l-tyrosine solubles dans l'eau et procede pour leur preparation
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
RU94040856A (ru) 1992-03-03 1996-08-20 Дайити Фармасьютикал Ко. Вакцина для перорального введения
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
DE69426077T3 (de) 1993-05-25 2004-09-02 Wyeth Holdings Corp. Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
JPH09502604A (ja) 1993-08-27 1997-03-18 エンテリック リサーチ ラボラトリーズ インコーポレイテッド Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ抗原、並びにそれらの製造及び利用
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5646115A (en) 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
AU4977896A (en) 1995-02-17 1996-09-04 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
GB9508785D0 (en) 1995-04-29 1995-06-21 Smithkline Beecham Plc Novel compositions
US5762943A (en) 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5973128A (en) 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CN1326564C (zh) 1997-04-01 2007-07-18 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
AU7983198A (en) 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CA2319380A1 (en) 1997-11-10 1999-05-20 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
EP1086228A1 (de) * 1998-06-12 2001-03-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Rekombinante herstellung vom toxoplasma sag1 antigen
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2000050078A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
HUP0200958A3 (en) 1999-04-23 2004-11-29 Pharmexa As Method for down-regulating il5 activity
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
GB9924529D0 (en) 1999-10-15 1999-12-15 Smithkline Beecham Biolog Novel compounds
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
AU4877799A (en) 2000-06-08
NZ337885A (en) 2001-01-26
AU766251B2 (en) 2003-10-09
KR100642877B1 (ko) 2006-11-13
JP2000103745A (ja) 2000-04-11
JP4743928B2 (ja) 2011-08-10
GB2341801B (en) 2003-10-29
CA2282779C (en) 2011-02-01
GB9922121D0 (en) 1999-11-17
EP0988862B1 (de) 2006-11-29
US6440426B1 (en) 2002-08-27
US7815920B2 (en) 2010-10-19
JP2010265330A (ja) 2010-11-25
ES2277413T3 (es) 2007-07-01
DE69934179D1 (de) 2007-01-11
CA2282779A1 (en) 2000-03-21
GB9820525D0 (en) 1998-11-11
KR20000023273A (ko) 2000-04-25
DK0988862T3 (da) 2006-12-27
EP0988862A2 (de) 2000-03-29
US20030007977A1 (en) 2003-01-09
EP0988862A3 (de) 2001-06-20
GB2341801A (en) 2000-03-29
DE69934179T2 (de) 2007-04-19
PT988862E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
ATE346610T1 (de) Zusammensetzung enthaltend, ein antigen, ein th-1 induzierendes adjuvans und eine im wasser schwer lösliche aminosäure, zur verwendung in der immunisierung
DE60029589D1 (de) Verfahren zur herstellung von azithromycin
ATE118552T1 (de) Verwendung eines schwer löslichen salzes einer heteropolysäure zur bestimmung eines analyts, entsprechendes bestimmungsverfahren sowie hierfür geeignetes mittel.
ATE124405T1 (de) 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel.
DK0406856T3 (da) Stabiliseret FGF-komposition og fremstilling heraf
FI951184A0 (fi) Taikinaa sisältävä yhdistelmä sekä menetelmä sen valmistamiseksi
NO864556L (no) Fremgangsmaate ved fremstilling av insulinpreparat.
DK0909562T3 (da) Injektionspræparat indeholdende en lipid A analog og fremgangsmåde til fremstilling deraf
EP0963982A3 (de) Neue Diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel
DE69533974D1 (de) Zusammensetzung zur Gewichtserhöhung von Vieh, die ein Ionophore und Selenium enthält
ATE177785T1 (de) Mutante des respiratory-syncytial-virus (rs- virus) und eine eine solche mutante enthaltende pharmazeutische zusammensetzung
DE69107031D1 (de) Thexyl-trialkoxysilane, Verfahren zur Herstellung und deren Verwendung.
ATE177141T1 (de) Verfahren zur stabilisierung eines kontaktlinsenpräparats
ATE121420T1 (de) Verfahren zur herstellung von 3-(l-pyroglutamyl)- l-thiazolidin-4-carbonsäure-derivaten.
DK88087A (da) Tricyklisk 5-(3-chlor-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo-(c,f)-(1,2)-thiazepin-11-yl)-amino-pentansyrederivat, fremgangsmaade til fremstilling deraf og farmaceutiske midler indeholdende dem
ATE92469T1 (de) Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung.
DE69026087D1 (de) Substituierte 2-imidazoline und verfahren zur herstellung sowie deren verwendung
DE3852105D1 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
ATE151996T1 (de) Kit zur einführung eines fremdkörpers, der geeignet zur identifikation eines tieres ist
DE60036758D1 (de) Verfahren zur Herstellung von optisch aktiver 3,3,3-Trifluor-2-hydroxy-2-methylpropionsäure und deren Salze
DE69823981D1 (de) Verwendung von Peptidverbindungen zur Behandlung von SLE
ES2081878T3 (es) Procedimiento para la preparacion discontinua de l-carnitina por via microbiologica.
ES2052797T3 (es) Procedimiento para la obtencion de heteroaromatos de cinco miembros que contienen nitrogeno.
DE69004204D1 (de) 2,4-Pentandionmonosulfonsäure und Verfahren zu ihrer Herstellung.
DE59003230D1 (de) Verfahren zur Herstellung von 2,4- bzw. 2,6-Dihalogen-anilin.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0988862

Country of ref document: EP